• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在高效抗逆转录病毒治疗时代优化CD4检测频率

Optimizing frequency of CD4 assays in the era of highly active antiretroviral therapy.

作者信息

Gaur Aditya H, Flynn Patricia M, Bitar Wally, Liang Hua

机构信息

Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.

出版信息

AIDS Res Hum Retroviruses. 2013 Mar;29(3):418-22. doi: 10.1089/AID.2012.0175. Epub 2012 Oct 31.

DOI:10.1089/AID.2012.0175
PMID:23016543
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3581070/
Abstract

Current HIV guidelines recommend monitoring CD4 counts every 3-4 months. In the era of highly active antiretroviral therapy (HAART) and HIV PCR, this retrospective study reexamines the required frequency of the CD4 assay. Predictor variables, including age, previous CD4 count, HIV viral load (VL), time interval since last VL and CD4 count (TINT), and antiretroviral history, were abstracted. A recursive partitioning-based regression tree analysis was used to determine if the absolute current CD4 count was above or below the age appropriate Pneumocystis jiroveci pneumonia (PCP) prophylaxis cutoff. We analyzed concurrently obtained VLs and CD4 count including 601 results from 43 HIV-infected children aged 1-<6 years (Group I) and 1,364 results from 93 children/adolescents 6-<23 years (Group II). Using 75% of observations to build a predictive model (learning dataset), the ability to correctly predict the range of the outcome variable in the remaining 25% of observations (training dataset) was 93% in Group I and 97% in Group II. Predictor variables included age, recent VL and CD4 count, and TINT. A total of 1,000 repeats of this model building using randomly selected observations showed a correct predictive ability of 89.6% [standard error (SE) 2.3%] in Group I and 95.6% (SE 1%) in Group II. The ability of a classification tree to determine if the current CD4 count is above or below the age-specific cutoff for PCP prophylaxis is very good and allows less frequent CD4 assays. The principles underlying this modeling-based approach have broad applicability and cost saving implications.

摘要

当前的艾滋病病毒指南建议每3 - 4个月监测一次CD4细胞计数。在高效抗逆转录病毒治疗(HAART)和艾滋病病毒聚合酶链反应(HIV PCR)时代,这项回顾性研究重新审视了CD4检测所需的频率。提取了预测变量,包括年龄、既往CD4细胞计数、艾滋病病毒载量(VL)、自上次VL和CD4细胞计数以来的时间间隔(TINT)以及抗逆转录病毒治疗史。使用基于递归划分的回归树分析来确定当前绝对CD4细胞计数是高于还是低于适合年龄的耶氏肺孢子菌肺炎(PCP)预防临界值。我们分析了同时获得的VL和CD4细胞计数,包括来自43名1 - <6岁感染艾滋病病毒儿童(第一组)的601份结果以及来自93名6 - <23岁儿童/青少年(第二组)的1364份结果。使用75%的观察值构建预测模型(学习数据集),在其余25%的观察值(训练数据集)中正确预测结果变量范围的能力在第一组为93%,在第二组为97%。预测变量包括年龄、近期VL和CD4细胞计数以及TINT。使用随机选择的观察值对该模型构建进行总共1000次重复,结果显示在第一组中正确预测能力为89.6% [标准误差(SE)2.3%],在第二组中为95.6%(SE 1%)。分类树确定当前CD4细胞计数高于还是低于PCP预防的年龄特异性临界值的能力非常好,并且可以减少CD4检测的频率。这种基于建模方法的基本原理具有广泛的适用性和节省成本的意义。

相似文献

1
Optimizing frequency of CD4 assays in the era of highly active antiretroviral therapy.在高效抗逆转录病毒治疗时代优化CD4检测频率
AIDS Res Hum Retroviruses. 2013 Mar;29(3):418-22. doi: 10.1089/AID.2012.0175. Epub 2012 Oct 31.
2
Discontinuation of Pneumocystis jirovecii pneumonia prophylaxis with CD4 count <200 cells/µL and virologic suppression: a systematic review.以 CD4 计数<200 个/µL 且病毒学抑制为标准停用预防卡氏肺孢子菌肺炎:系统评价。
PLoS One. 2011;6(12):e28570. doi: 10.1371/journal.pone.0028570. Epub 2011 Dec 16.
3
Pneumocystis jiroveci pneumonia prophylaxis is not required with a CD4+ T-cell count < 200 cells/microl when viral replication is suppressed.当病毒复制受到抑制时,CD4 + T细胞计数<200个/微升时无需进行耶氏肺孢子菌肺炎预防。
AIDS. 2007 Aug 20;21(13):1711-5. doi: 10.1097/QAD.0b013e32826fb6fc.
4
Decrease in hospitalization and mortality rates among children with perinatally acquired HIV type 1 infection receiving highly active antiretroviral therapy.接受高效抗逆转录病毒治疗的围产期获得性1型艾滋病毒感染儿童的住院率和死亡率下降。
Clin Infect Dis. 2004 Sep 1;39(5):725-31. doi: 10.1086/423178. Epub 2004 Aug 16.
5
Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?对于病毒学抑制的 HIV 感染且 CD4 细胞计数<200 个/μL 的患者,停止原发性卡氏肺孢子虫肺炎预防是否安全?
Clin Infect Dis. 2010 Sep 1;51(5):611-9. doi: 10.1086/655761.
6
Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy.接受高效抗逆转录病毒治疗的HIV-1感染患者卡氏肺孢子虫肺炎预防性治疗的停药情况。
Lancet. 1999 Jan 16;353(9148):201-3. doi: 10.1016/S0140-6736(98)07204-3.
7
Viral load predicts new world health organization stage 3 and 4 events in HIV-infected children receiving highly active antiretroviral therapy, independent of CD4 T lymphocyte value.病毒载量可预测接受高效抗逆转录病毒治疗的 HIV 感染儿童新出现的世界卫生组织第 3 期和第 4 期事件,而与 CD4 T 淋巴细胞计数无关。
Clin Infect Dis. 2010 Dec 1;51(11):1325-33. doi: 10.1086/657119. Epub 2010 Nov 1.
8
Withdrawal of Pneumocystis jirovecii prophylaxis in HIV-infected children under highly active antiretroviral therapy.在接受高效抗逆转录病毒治疗的HIV感染儿童中停用耶氏肺孢子菌预防治疗
AIDS. 2005 Dec 2;19(18):2103-8. doi: 10.1097/01.aids.0000194795.20928.2b.
9
Pneumocystis jirovecii prophylaxis discontinuation based upon total lymphocyte count in HIV-infected adults treated with antiretroviral therapy.
Int J STD AIDS. 2010 Jun;21(6):406-9. doi: 10.1258/ijsa.2009.009090.
10
Pneumocystis carinii pneumonia recurrence in HIV patients on highly active antiretroviral therapy: secondary prophylaxis.接受高效抗逆转录病毒治疗的艾滋病患者中卡氏肺孢子虫肺炎的复发:二级预防
J Acquir Immune Defic Syndr. 2001 Feb 1;26(2):151-8. doi: 10.1097/00042560-200102010-00007.

本文引用的文献

1
PEPFAR and maximizing the effects of global health assistance.总统防治艾滋病紧急救援计划与全球卫生援助效果的最大化。
JAMA. 2012 May 16;307(19):2097-100. doi: 10.1001/jama.2012.4989.
2
Discordant immunological and virological responses to antiretroviral therapy.对抗逆转录病毒疗法的免疫和病毒学反应不一致。
J Antimicrob Chemother. 2006 Sep;58(3):506-10. doi: 10.1093/jac/dkl263. Epub 2006 Jul 19.
3
Discordant immunologic and virologic responses to highly active antiretroviral therapy are associated with increased mortality and poor adherence to therapy.对高效抗逆转录病毒疗法的免疫和病毒学反应不一致与死亡率增加及治疗依从性差有关。
J Acquir Immune Defic Syndr. 2005 Nov 1;40(3):288-93. doi: 10.1097/01.qai.0000182847.38098.d1.
4
A decision tree for tuberculosis contact investigation.用于结核病接触者调查的决策树。
Am J Respir Crit Care Med. 2002 Oct 15;166(8):1122-7. doi: 10.1164/rccm.200202-124OC.
5
Quality standard for the enumeration of CD4+ lymphocytes in infants and children exposed to or infected with human immunodeficiency virus.暴露于或感染人类免疫缺陷病毒的婴幼儿CD4+淋巴细胞计数的质量标准。
Clin Infect Dis. 1995 Aug;21 Suppl 1:S134-5. doi: 10.1093/clinids/21.supplement_1.s134.